Adverse Effects of Transfusion

Cancer Control

Volumn 22, Issue 1, 2015, Pages 16-25

  Dasararaju, Radhika ^a   Marques, Marisa B ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DIPHENHYDRAMINE; PARACETAMOL; STEROID;

ACUTE HEMOLYTIC TRANSFUSION REACTION; ALLOIMMUNIZATION; ARTICLE; BLOOD TRANSFUSION REACTION; COOMBS TEST; DELAYED HEMOLYTIC TRANSFUSION REACTION; DISEASE ASSOCIATION; ERYTHROCYTE; FATALITY; FEBRILE NONHEMOLYTIC TRANSFUSION REACTION; GRAFT VERSUS HOST REACTION; HUMAN; HYPERVOLEMIA; IMMUNOMODULATION; IRON OVERLOAD; LEUKEMIA; MICROBIAL CONTAMINATION; PATIENT MONITORING; POSTTRANSFUSION PURPURA; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TEMPERATURE MEASUREMENT; THROMBOCYTE; TRANSFUSION ASSOCIATED CIRCULATORY OVERLOAD; TRANSFUSION RELATED ACUTE LUNG INJURY; ACUTE LUNG INJURY; ADVERSE EFFECTS; BLOOD TRANSFUSION; COMPLICATION; NEOPLASMS; SAFETY; SHOCK;

ACUTE LUNG INJURY; BLOOD TRANSFUSION; GRAFT VS HOST DISEASE; HUMANS; IRON OVERLOAD; NEOPLASMS; SAFETY; SHOCK;

EID: 84924778157     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481502200104     Document Type: Article

References (70)

1. Huh YO, Lichtiger B. Transfusion reactions in patients with cancer. Am J Clin Path. 1987;87(2):253-257.
2. Vamvakas EC. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transf Med Rev. 2005;19(3):181-199.
3. Geiger TL, Howard SC. Acetaminophen and diphenhydramine pre­medication for allergic and febrile nonhemolytic transfusion reactions: good prophylaxis or bad practice? Transf Med Rev. 2007;21(1):1-12.
4. Patterson BJ, Freedman J, Blanchette V, et al. Effect of premedication guidelines and leukoreduction on the rate of febrile nonhaemolytic platelet transfusion reactions. Transf Med (Oxford, England). 2000;10(3):199-206.
5. Ezidiegwu CN, Lauenstein KJ, Rosales LG, et al. Febrile nonhemolytic transfusion reactions. Management by premedication and cost implications in adult patients. Arch Path Lab Med. 2004;128(9):991-995.
6. Kennedy LD, Case LD, Hurd DD, et al. A prospective, randomized, double-blind controlled trial of acetaminophen and diphenhydramine pretrans­fusion medication versus placebo for the prevention of transfusion reactions. Transfusion. 2008;48(11):2285-2291.
7. Marti-Carvajal AJ, Solá I, González LE, et al. Pharmacological inter­ventions for the prevention of allergic and febrile non-haemolytic transfusion reactions. Cochrane Database Syst Rev. 2010(6):CD007539.
8. US Food and Drug Administration. Transfusion/donation fatalities. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities. Accessed November 5, 2014.
9. Tinegate H, Birchall J, Gray A, et al; BCSH Blood Transfusion Task Force. Guideline on the investigation and management of acute transfusion reactions. Br J Haematol. 2012;159(2):143-153.
10. Liu C, Zhao W, Christ GJ, et al. Nitric oxide scavenging by red cell microparticles. Free Radic Biol Med. 2013;65:1164-1173.
11. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Trans­fusion. 2004;44(12):1774-1789.
12. Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: definition and review. Crit Care Med. 2005;33(4):721-726.
13. Andrzejewski C Jr, Casey MA, Popovsky MA. How we view and ap­proach transfusion-associated circulatory overload: pathogenesis, diagnosis, management, mitigation, and prevention. Transfusion. 2013;53(12):3037-3047.
14. Hirayama F. Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment. Br J Hae­matol. 2013;160(4):434-444.
15. Zilberstein J, McCurdy MT, Winters ME. Anaphylaxis. J Emerg Med. 2014;47(2):182-187.
16. Maskens C, Downie H, Wendt A, et al. Hospital-based transfusion error tracking from 2005 to 2010: identifying the key errors threatening patient transfusion safety. Transfusion. 2014;54(1):66-73.
17. Zantek ND, Koepsell SA, Tharp DR Jr, et al. The direct antiglobulin test: a critical step in the evaluation of hemolysis. Am J Hematol. 2012;87(7):707-709.
18. Nakagawa M, Toy P. Acute and transient decrease in neutrophil count in transfusion-related acute lung injury: cases at one hospital. Transfusion. 2004;44(12):1689-1694.
19. Marques MB, Tuncer HH, Divers SG, et al. Acute transient leukopenia as a sign of TRALI. Am J Hematol. 2005;80(1):90-91.
20. Zhou L, Giacherio D, Cooling L, et al. Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload. Transfusion. 2005;45(7):1056-1063.
21. Bux J, Sachs UJ. Pulmonary transfusion reactions. Transfus Med Hemother. 2008;35(5):337-345.
22. Stowell SR, Winkler AM, Maier CL, et al. Initiation and regulation of complement during hemolytic transfusion reactions. Clin Dev Immunol. 2012;2012:307093.
23. Cid J, Harm SK, Yazer MH. Platelet transfusion - the art and science of compromise. Transfus Med Hemother. 2013;40(3):160-171.
24. US Food and Drug Administration. Guidance for industry: circular of information for the use of human blood and blood components. http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/ucm364565.htm. Accessed November 5, 2014.
25. Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood. 2005;106(5):1532-1537.
26. Pintova S, Bhardwaj AS, Aledort LM. IVIG--a hemolytic culprit. N Engl J Med. 2012;367(10):974-976.
27. Michelis FV, Branch DR, Scovell I, et al. Acute hemolysis after intra­venous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes. Trans­fusion. 2014;54(3):681-690.
28. Bernard GR, Artigas A, Brigham KL, et al; Consensus Committee. Report of the American-European Consensus conference on acute respiratory distress syndrome: definitions, mechanisms, relevant outcomes, and clinical trial coordination. J Crit Care. 1994;9(1):72-81.
29. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion. 1985;25(6):573-577.
30. Silliman CC, Bjornsen AJ, Wyman TH, et al. Plasma and lipids from stored platelets cause acute lung injury in an animal model. Transfusion. 2003;43(5):633-640.
31. West FB, Silliman CC. Transfusion-related acute lung injury: advances in understanding the role of proinflammatory mediators in its genesis. Expert Rev Hematol. 2013;6(3):265-276.
32. Cherry T, Steciuk M, Reddy VV, et al. Transfusion-related acute lung injury: past, present, and future. Am J Clin Path. 2008;129(2):287-297
33. Silliman CC, Boshkov LK, Mehdizadehkashi Z, et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood. 2003;101(2):454-462.
34. Finlayson J, Grey D, Kavanagh L, et al. Transfusion-related acute lung injury in a neutropenic patient. Intern Med J. 2011;41(8):638-641.
35. Eder AF, Dy BA, Perez JM, et al. The residual risk of transfusion-re­lated acute lung injury at the American Red Cross (2008-2011): limitations of a predominantly male-donor plasma mitigation strategy. Transfusion. 2013;53(7):1442-1449.
36. Vlaar AP, Juffermans NP. Transfusion-related acute lung injury: a clinical review. Lancet. 2013;382(9896):984-994.
37. Menis M, Anderson SA, Forshee RA, et al. Transfusion-associated circulatory overload (TACO) and potential risk factors among the inpatient US elderly as recorded in Medicare administrative databases during 2011. Vox Sang. 2014;106(2):144-152.
38. Alam A, Lin Y, Lima A, et al. The prevention of transfusion-associated circulatory overload. Transfus Med. 2013;27(2):105-112.
39. Centers for Disease Control and Prevention. National Healthcare Safety Network Biovigilance Component Hemovigilance Module Surveillance Pro­tocol. Version 2.1.3. Atlanta, GA: National Center for Emergency and Zoonotic Infections Diseases; 2014. http://www.cdc.gov/nhsn/PDFs/hemovigModulePro­tocol_current.pdf. Accessed November 5, 2014.
40. Brecher ME, Blajchman MA, Yomtovian R, et al. Addressing the risk of bacterial contamination of platelets within the United States: a history to help illuminate the future. Transfusion. 2013;53(1):221-231.
41. Young C, Chawla A, Berardi V, et al; Babesia Testing Investigational Containment Study Group. Preventing transfusion-transmitted babesiosis: preliminary experience of the first laboratory-based blood donor screening program. Transfusion. 2012;52(7):1523-1529.
42. Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013;28(3):145-284.
43. Johnson ST, Van Tassell ER, Tonnetti L, et al. Babesia microti real-time polymerase chain reaction testing of Connecticut blood donors: potential im­plications for screening algorithms. Transfusion. 2013;53(11):2644-2649.
44. American Red Cross. Infectious disease testing for donated blood. http://www.redcrossblood.org/learn-about-blood/blood-testing. Accessed November 5, 2014.
45. Yu MY, Alter HJ, Virata-Theimer ML, et al. Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples. Transfusion. 2010;50(8):1712-1721.
46. Ricci KS, Martinez F, Lichtiger B, et al. Septic transfusion reactions during blood transfusion via indwelling central venous catheters. Transfusion. 2014;54(10):2412-2418.
47. Cohn CS, Stubbs J, Schwartz J, et al. A comparison of adverse reaction rates for PAS C versus plasma platelet units. Transfusion. 2014;54(8):1927-1934.
48. Wang RR, Triulzi DJ, Qu L. Effects of prestorage vs poststorage leukore­duction on the rate of febrile nonhemolytic transfusion reactions to platelets. Am J Clin Path. 2012;138(2):255-259.
49. Tormey CA, Stack G. Limiting the extent of a delayed hemolytic trans­fusion reaction with automated red blood cell exchange. Arch Pathol Lab Med. 2013;137(6):861-864.
50. Ness PM, Shirey RS, Thoman SK, et al. The differentiation of delayed serologic and delayed hemolytic transfusion reactions: incidence, long-term serologic findings, and clinical significance. Transfusion. 1990;30(8):688-693.
51. Alter HJ, Klein HG. The hazards of blood transfusion in historical per­spective. Blood. 2008;112(7):2617-2626.
52. Higgins MJ, Blackall DP. Transfusion-associated graft-versus-host disease: a serious residual risk of blood transfusion. Curr Hematol Rep. 2005;4(6):470-476.
53. Agbaht K, Altintas ND, Topeli A, et al. Transfusion-associated graft-versus-host disease in immunocompetent patients: case series and review of the literature. Transfusion. 2007;47(8):1405-1411.
54. Sunul H, Erguven N. Transfusion-associated graft-versus-host disease. Transfus Apher Sci. 2013;49(2):331-333.
55. Uchida S, Tadokoro K, Takahashi M, et al. Analysis of 66 patients with definitive transfusion-associated graft-versus-host disease and the effect of universal irradiation of blood. Transfus Med. 2013;23(6):416-422.
56. Shtalrid M, Shvidel L, Vorst E, et al. Post-transfusion purpura: a chal­lenging diagnosis. Isr Med Assoc J. 2006;8(10):672-674.
57. Heikal NM, Smock KJ. Laboratory testing for platelet antibodies. Am J Hematol. 2013;88(9):818-821.
58. Heal JM, Phipps RP, Blumberg N. One big unhappy family: transfu­sion alloimmunization, thrombosis, and immune modulation/inflammation. Transfusion. 2009;49(6):1032-1036.
59. Bauer MP, Wiersum-Osselton J, Schipperus M, et al. Clinical predictors of alloimmunization after red blood cell transfusion. Transfusion. 2007;47(11):2066-2071.
60. Sanz C, Nomdedeu M, Belkaid M, et al. Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomono­cytic leukemia. Transfusion. 2013;53(4):710-715.
61. Pavenski K, Freedman J, Semple JW. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and manage­ment. Tissue Antigens. 2012;79(4):237-245.
62. O’Brien KL, Haspel RL, Uhl L. Anti-D alloimmunization after D-incom­patible platelet transfusions: a 14-year single-institution retrospective review. Transfusion. 2014;54(3):650-654.
63. Blumberg N, Heal JM. Effects of transfusion on immune function. Can­cer recurrence and infection. Arch Pathol Lab Med. 1994;118(4):371-379.
64. Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev. 2007;21(6):327-348.
65. Refaai MA, Blumberg N. Transfusion immunomodulation from a clinical perspective: an update. Expert Rev Hematol. 2013;6(6):653-663.
66. Goldberg SL, Chen E, Corral M, et al. Incidence and clinical compli­cations of myelodysplastic syndromes among United States Medicare bene­ficiaries. J Clin Oncol. 2010;28(17):2847-2852.
67. Andrews NC, Schmidt PJ. Iron homeostasis. Annu Rev Physiol. 2007;69:69-85.
68. Mitchell M, Gore SD, Zeidan AM. Iron chelation therapy in myelodysplastic syndromes: where do we stand? Expert Rev Hematol. 2013;6(4):397-410.
69. Dzik WH. Emily Cooley lecture 2002: transfusion safety in the hospital. Transfusion. 2003;43(9):1190-1198.
70. Carson JL, Hebert PC. Should we universally adopt a restric­tive approach to blood transfusion? It’s all about the number. Am J Med. 2014;127(2):103-104.